| Prev Close | 77.32 |
| Open | 77.61 |
| Day Low/High | 77.59 / 79.33 |
| 52 Wk Low/High | 71.59 / 94.20 |
| Volume | 552.78K |
BioMarin Pharmaceutical Inc. (BMRN)
78.96
1.60
2.10
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 185.00B |
| Market Cap | 14.38B |
| P/E Ratio | 19.64 |
| Div & Yield | N.A. (N.A) |
Latest News
Options Play of the Week: Wash, Rinse, Repeat
BioMarin has turned into a synthetic dividend play that has been returning yields in the low teens every six months or so.
BioMarin's FDA Setback Opens New Opportunities for the Stock
A simple covered call strategy seems appropriate here.
There's No Outside Force Having Any Impact on This Market Right Now
The hardest thing to do is to stick with the momentum and not give in to the temptation to sell prematurely.
Adding to My Biotech Positions When Profit-Taking Hits
Here's my strategy which has worked particularly well.
Biotech's Big Week Finds a Big Winner in Adaptimmune
The clinical stage company sees its shares climb after announcing some significant news during this week's J.P. Morgan Healthcare Conference.
4 Favorite Biotech Stock Picks for 2020
The Medical Technology Stock Letter's top pick rose 357% in 2019.
Jim Cramer: Think Stocks Are Too Pricey? These Big Takeovers Prove They're Not
We're seeing lots of companies snapping up their peers, and the market is applauding.
BioMarin Can Trade Sideways in the Near-Term, Use It as a Buying Opportunity
Let's visit with the charts to see if things are still on track.
The Winds Have Changed for BioMarin
I am looking for higher prices.
3 Biotech Plays That Would Work as Covered Calls
The SPDR S&P Biotech ETF, Alexion Pharmaceuticals and BioMarin Pharmaceuticals set up nicely for this options strategy.
Otezla Price Under Microscope -- but Look Closely and It Checks Out
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
A Handful of Small Biotechs That Make for Merger Chatter
The names include a veterinary drug concern plus companies with successful drugs on the market.
2 Stocks You Definitely Should Consider Shorting This Week
These 'Bearish Bets' are showing both technical and quantitative deterioration.
Here's How I'm Playing an Increasingly Volatile Market With These 2 Biotechs
I am incrementally using buy-write option orders to add some shares to core holdings.
10 Speculative Stock Plays in the Biotech Sector
For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.
Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died
Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.
Two Small-Caps and One Mid-Cap Stock I Like So Far in 2019
It has been a better year for the Russell 2000 and the small-caps it represents.
Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop
It is all about perception, and here are strong names to pick up on market weakness.
Charts: BioMarin Pharmaceutical Could Rise 30% From Here
I have not seen a bullish breakout from a large base pattern in a while.
BioMarin Paces a Very Strong Biotech Group
Here's how BMRN's chart looks after its blistering gains.
These Biotechs Are Movers Today
The market is down across the board as one might expect given escalating trade tensions today. However, losses are slight in this context in the first hour of trading. Given the option expiration date, volatility could pick up later in the day. Some...
Probing the Long Side of BioMarin
Latest surge boosts chances of breakout in shares of BioMarin.
BioMarin Pharmaceutical Is Doing Better but Patience Is Needed
The upswing is welcomed but it still is not an important breakout of the two-year sideways pattern.
Here's My Take on Biotech Stocks
I think M&A activity will pick up markedly going forward across the industry.
Why I Stay Very Focused on My Individual Stocks
I do not need to come up with any grand arguments for a bullish or bearish bias. It happens by default.
Allergan, BioMarin Hold Promise for 2018
The stocks of these two larger-cap biopharma names seem poised to stage comebacks next year.
